Redefining blood-based biomarker quantification for neurodegenerative diseases and beyond
Explore real-world applications of Taudia’s ultrasensitive, flexible platform designed to make blood-based biomarker detection accurate, reproducible, and scalable.
Reliable, reproducible blood biomarker detection made simple
At Taudia, we’ve redefined what’s possible in protein biomarker detection. Our washed-based assay makes ultrasensitive blood biomarker testing both highly reproducible and simple.
With flexible workflows for every bench, Taudia’s platform makes ultrasensitive protein detection accessible in any setting, from discovery labs to global clinical trials. The result: faster, more reliable data that accelerates therapeutic development and democratizes diagnostic access.
Scalable blood tests that advance early detection of neurodegenerative diseases
There is an urgent need for early, accurate, and scalable diagnostics in neurodegenerative diseases. Current gold standards—PET and CSF—remain invasive, costly, and impractical for broad use.
Taudia provides an alternative by enabling:
- Accessible biomarker quantification without expensive capital equipment
- Flexible workflows for broad applications
- Reproducible, reliable results on any bench
With Taudia’s platform technology, any laboratory can quantify low abundance biomarkers like pTau-217. We are currently focused on the neuro field, creating assays to fuel researchers tackling neurodegenerative diseases including Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and Frontal Temporal Dementia (FTD).
Building the future of brain health diagnostics with ultrasensitive blood biomarker tests
Maintaining optimal brain health involves more than what symptoms can reveal. Emerging research shows that blood biomarker tracking offers promising, non-invasive insights into neural integrity long before clinical signs emerge.
Studies have identified several blood biomarkers associated with neuronal and glial integrity, such as neurofilament light (NfL), β-synuclein, and glial fibrillary acidic protein (GFAP) in neurodegenerative contexts. These markers reflect processes such as neuronal injury or glial response, providing a window into brain aging and pathology that clinical evaluations alone cannot capture.
Taudia’s ultrasensitive, flexible, and scalable platform is well-positioned to deliver future-ready blood test solutions that will help people track and protect their cognitive well-being. With a next-generation of blood biomarker tests, individuals and clinicians could monitor trends, detect deviations, and act earlier to safeguard brain health.
Let's shape the future of blood-based biomarker applications together
We envision ultrasensitive blood biomarker quantification as an accessible tool for monitoring brain health. From early discovery through companion diagnostics, Taudia empowers partners to bring clarity and confidence to the fight against complex neurological diseases.